Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
Clinical Advances in Hematology & Oncology : H&O|December 16, 2010
Advances in targeted therapy for melanomaPhilip Friedlander, F Stephen HodiThe Journal of Clinical and Aesthetic Dermatology|November 17, 2016
Systemic Therapies for Late-stage MelanomaPeter W Hashim, Philip Friedlander, Gary GoldenbergCancers|January 13, 2021
Current Melanoma Treatments: Where Do We Stand?Alvaro Moreira, Lucie Heinzerling, Nina Bhardwaj, et al.Oncogene|January 16, 2002
The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cellsNicole Baptiste, Philip Friedlander, Xinbin Chen, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 20, 2017
Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case ReportJulia M Zecchini, Sara Kim, Kendra Yum, et al.The Journal of Community and Supportive Oncology|February 11, 2016
Impact of inpatient radiation on length of stay and health care costsSofya Pintova, Randall F Holcombe, Seth Blacksburg, et al.Dermatology Online Journal|July 5, 2020
Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexateAakaash Varma, Philip Friedlander, Ellen H De Moll, et al.Anticancer Research|March 28, 2023
Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in MelanomaPhilip Friedlander, Lee Roy Morgan, Edmund N Benes, et al.Journal for Immunotherapy of Cancer|September 20, 2018
A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumabPhilip Friedlander, Kevin Wood, Karl Wassmann, et al.Journal for Immunotherapy of Cancer|November 17, 2024
Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanomaMatthew R Kudelka, Allison L Richards, Philip Friedlander, et al.Pageof 3